Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）

DRUG4 trials

Sponsors

Tianjin Medical University Cancer Institute and Hospital, Sun Yat-sen University, Zhujiang Hospital

Conditions

Bladder CancerHNSCCHepatocellular CarcinomaHepatocellular Carcinoma Non-resectableIvonescimabMuscle-invasive Bladder CancerNasopharyngeal Carcinoma (NPC)OPSCC

Phase 1

Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

Not yet recruitingNCT06957561

Sun Yat-sen UniversityBladder Cancer, Muscle-invasive Bladder Cancer

Start: 2025-04-30End: 2029-05-01Target: 30Updated: 2025-05-04

Phase 2

Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）.

RecruitingNCT06375486

Tianjin Medical University Cancer Institute and HospitalHepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable

Start: 2024-03-14End: 2026-06-15Target: 30Updated: 2024-04-19

Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma

Not yet recruitingNCT07064902

Sun Yat-sen UniversityNasopharyngeal Carcinoma (NPC)

Start: 2026-08-01End: 2028-06-30Target: 48Updated: 2026-07-16

Unknown Phase

Objective Response Rate of Ivonescimab With Chemotherapy in Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma

RecruitingNCT07686575

Zhujiang HospitalHNSCC, Ivonescimab, OPSCC +1

Start: 2026-01-26End: 2028-08-30Target: 20Updated: 2026-07-07

Related Papers

Ivonescimab (PD-1/VEGF bispecific antibody) combined with HAIC for first-line treatment of unresectable hepatocellular carcinoma (uHCC): A prospective, single-arm phase II study.

Journal of Clinical Oncology2025-05-28